Targeted therapies for diarrhea-predominant irritable bowel syndrome

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 69-100

  Olden, Kevin W ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Alosetron; Antibiotic therapy; Antidepressant therapy; Evidence; Targeted review

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; IMIPRAMINE; LOPERAMIDE; NEOMYCIN; PAROXETINE; PLACEBO; RIFAXIMIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; CONSTIPATION; CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME; DIARRHEA; DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME; DIARRHEA PREDOMINAT IRRITABLE BOWEL SYNDROME; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG TOLERABILITY; FECES ANALYSIS; GASTROENTEROLOGY; HUMAN; INTESTINE FLORA; IRRITABLE COLON; NAUSEA; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 84863915002     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S29023     Document Type: Review

References (30)

1. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13:738-741.
2. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:678-684.
3. Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 1987;32:257-266.
4. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31.
5. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53:108-115.
6. Abdul-Baki H, El Hajj II, Elzahabi L, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol. 2009;15:3636-3642.
7. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219-228.
8. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99:914-920.
9. Masand PS, Pae CU, Krulewicz S, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50:78-86.
10. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55:1095-1103.
11. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563.
12. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333.
13. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea associated irritable bowel syndrome: short term treatment leading to long term sustained response [abstract T1390]. Gastroenterology. 2008;134 suppl. 1:A-545.
14. Ringel Y, Palsson OS, Zakko SF. Predictors of clinical response from a hase 2 multi-center efficacy trial using rifaximin, a gut-selective, non-absorbed antibiotic for the treatment of diarrhea associated irritable bowel syndrome [abstract T1411]. Gastroenterology. 2008;134 Suppl. 1:A550.
15. Pimentel M, Ringel Y, Brooks C, Bortey E, Forbes W. Severity of irritable bowel syndrome-related symptoms predicts clinical response to the nonsystemic antibiotic rifaximin [abstract P1065]. Presented at the 73rd annual meeting of the American College of Gastroenterology; October 3-8, 2008; Orlando, FL.
16. Chey WD, Talley NJ, Lembo A, Yu A, Bortey E. Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome [abstract P691]. Presented at the 73rd annual meeting of the American College of Gastroenterology; October 3-8, 2008; Orlando, FL.
17. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
18. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1159.
19. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14:23-34.
20. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035-1040.
21. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733-1740.
22. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:455-459.
23. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662-2670.
24. Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001;96:803-811.
25. Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2002;97:3139-3146.
26. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195-2203.
27. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675-682.
28. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115-123.
29. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709-1719.
30. Nicandro JPA, Shin P, Shringarpure R, Chuang E, Pan H. Alosetron is associated with improvements in treatment satisfaction and quality of life [abstract M1058]. Presented at the Digestive Disease Week 2010, May 1-5, 2010, New Orleans, LA.